EIP Pharma is a clinical stage therapeutics company developing small molecule drugs targeting neurodegenerative diseases such as Alzheimer's and Parkinson's. Their approach focuses on modulating neuroinflammation and neuroprotection pathways to improve cognitive function and slow disease progression.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like Alzheimer's and Parkinson's pose significant challenges due to the complex interplay of neuroinflammation and impaired neuroprotection, leading to cognitive decline and disease progression. Current treatments often provide limited symptomatic relief and do not effectively address the underlying disease mechanisms.
Solution
EIP Pharma is developing small molecule therapeutics designed to modulate neuroinflammation and enhance neuroprotection pathways, aiming to improve cognitive function and slow the progression of neurodegenerative diseases. Their approach focuses on selectively targeting key inflammatory mediators and promoting neuronal resilience to mitigate the damaging effects of these diseases. By addressing the root causes of neurodegeneration, EIP Pharma seeks to develop disease-modifying therapies that offer a more comprehensive and effective treatment strategy. These novel compounds are designed to cross the blood-brain barrier and exert their effects directly within the central nervous system.
Target Audience
The primary target audience includes individuals suffering from neurodegenerative diseases such as Alzheimer's and Parkinson's, as well as their caregivers and healthcare providers.
Features
- Small molecule drugs designed to modulate neuroinflammation
- Compounds that enhance neuroprotective pathways
- Focus on improving cognitive function in neurodegenerative diseases
- Potential for disease-modifying therapies
- Designed to cross the blood-brain barrier